Oral Anticoagulation and the Novel Oral Anticoagulants (NOACs):Where Are We at Midterm?

Academic Content

Program Overview

Faculty Presentations

Introduction Deepak L. Bhatt Elaine Hylek

Video Roundtable

Current Activity

Deepak L. Bhatt, MD, MPH
Interventional Cardiovascular Programs
Brigham & Women’s Hospital
Heart & Vascular Center
Harvard Medical School
Boston, Massachusetts

Overview: Anticoag & NOACs AFib Impact AFib in the USA AFib: Age Prevalence AFib: Age & Gender AFib: Age & Strokes Problems with Warfarin Warfarin INR Values & Stroke CHADS2 & AFib - Index Scores CHADS2 & AFib - Patient Scores The REACH Registry: CVD Events CHA2DS2-VASc Stroke Risk The HAS-BLED Risk Score Markov Decision Analysis Novel Oral Anticoagulants NOACS: Risk Prevention Data NOACS: Secondary Efficacy NOACS: Major Bleeding NOACS: Secondary Safety Potentially Preventable Strokes Anticoagulation in VTE Regulatory Approval Status

Return to:

The American Journal of Medicine

« Prev

Next »
Click Figure to Enlarge

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

The American Journal of Medicine

Print This Page

The REACH Registry: CVD Event Rates in Patients with AFib vs CHADS2 Score

Another interesting benefit of the CHADS₂ risk score is that it not only predicts risk of AFib-related stroke, it also appears to predict other vascular event rates in general in patients with AFib, as shown in the data from the REduction of Atherothrombosis for Continued Health (REACH) registry (Figure 11).[12]

Bhatt D. Am J Med 2014; 00.

References

[12]

Goto S, Bhatt DL, Röther J, et al; REACH Registry Investigators. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855-863.